BOSTON, April 24, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Partnerships in Clinical Trials named PAREXEL's Drew Garty, Senior Director, Product Management, the 2015 Clinical Innovator of the Year. The honor recognizes Mr. Garty's leadership of the product development team for the Company's Perceptive MyTrials® Data-Driven Monitoring solution.
After accepting the award Thursday night during the 2015 Partnership Awards in Boston, Mr. Garty stated, "The development of our Perceptive MyTrials Data-Driven Monitoring (DDM) solution was a significant team effort with a clear goal of meeting a customer need. I am honored to accept this award from Partnerships in Clinical Trials on behalf of the team in recognition of PAREXEL's innovative approach to risk-based monitoring."
On-site monitoring is a critical aspect of trial management, with the primary function of identifying and mitigating patient safety or data quality risks at investigative sites. The U.S. Food and Drug Administration (FDA) and other regulatory bodies have issued guidance to assist sponsors in developing risk-based monitoring strategies. The goal of these strategies is to enhance patient protection and improve trial data quality through more effective study oversight.
The Perceptive MyTrials Data-Driven Monitoring solution uses a unique algorithmic-based approach to clinical monitoring to determine risk and monitor workload, enabling flexible and scalable decision making. DDM allows drug developers to accurately identify study risks and efficiently determine the most effective monitoring interventions required. As a result, drug developers can enhance quality and patient safety, reduce costs and ensure regulatory compliance.
"Through the Perceptive MyTrials Data-Driven Monitoring solution, we have greater insights into study data. These insights can make clinical trial participation safer for patients, improve decision making during the drug development journey and offer cost efficiencies for sponsors," said Xavier Flinois, President of PAREXEL Informatics. "Our data-driven monitoring solution builds on PAREXEL's established history of developing innovative technologies to continuously improve clinical processes, and we are thrilled to be recognized by Partnerships in Clinical Trials."
About Partnership in Clinical Trials and the Partnership Awards
The Partnerships in Clinical Trials event is North America's largest conference serving the global clinical trials, operations and outsourcing community. The Partnership Awards honor the accomplishments of clinical trial leaders who have influenced change within the industry through innovation. The Clinical Innovator of the Year Award honors a person or company with a disruptive technology platform or a new way to optimize clinical development that has increased the efficiency of clinical trials.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, and Perceptive MyTrials are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of Quantum Solutions India and ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
Diana Martin, PAREXEL International
Tel: +1 781-434-5516
Email: [email protected]
Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019
Email: [email protected]
Jenny Gardynski, PAN Communications
Tel: +1 617-502-4300
Email: [email protected]
SOURCE PAREXEL International Corporation